MSH2 and neoplasm: Although several features (Amsterdam-II, Revised Bethesda, tumour location, deficient expression of the MSH6 and MSH2 genes) did not reach statistical significance, others (LS risk and deficient expression of the MLH1 and PMS2 genes) differed dramatically with respect to CRC outcome.